Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ALKS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants Wi… NCT07755410 · Attention Deficit Disorder With Hyperactivity (ADHD) ALKS 7290, Placebo | ALKS Alkermes, Inc. | Phase 2 | Recruiting | 312 | Jul 2027 | Registry ↗ |
| Oct 28, 2026 | A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressant… NCT07901179 · Major Depressive Disorder (MDD) ALKS 7290 Dose, Placebo | ALKS Alkermes, Inc. | Phase 2 | Recruiting | 180 | Jan 2028 | Registry ↗ |
| Oct 9, 2026 | A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia NCT06767683 · Narcolepsy Type 1, Narcolepsy Type 2 ALKS 2680, 4mg, ALKS 2680, 6mg | ALKS Alkermes, Inc. | Phase 2/3 | Recruiting | 786 | Jun 2030 | Registry ↗ |
| Oct 7, 2026 | A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Ty… NCT07540897 · Narcolepsy Type 1 ALKS 2680 Dose 1, ALKS 2680 Dose 2 | ALKS Alkermes, Inc. | Phase 3 | Recruiting | 150 | Jun 2027 | Registry ↗ |
| Oct 7, 2026 | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 NCT07502443 · Narcolepsy Type 2 ALKS 2680 Dose 1, ALKS 2680 Dose 2 | ALKS Alkermes, Inc. | Phase 3 | Recruiting | 176 | May 2027 | Registry ↗ |
| Oct 7, 2026 | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 NCT07455383 · Narcolepsy Type 1 ALKS 2680 Dose 1, ALKS 2680 Dose 2 | ALKS Alkermes, Inc. | Phase 3 | Recruiting | 150 | May 2027 | Registry ↗ |
| Sep 25, 2026 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomn… NCT06843590 · Idiopathic Hypersomnia ALKS 2680, Placebo | ALKS Alkermes, Inc. | Phase 2 | Active, not recruiting | 126 | Nov 2026 | Registry ↗ |
| Aug 14, 2026 | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schiz… NCT05303064 · Schizophrenia, Bipolar I Disorder OLZ/SAM, Olanzapine | ALKS Alkermes, Inc. | Phase 3 | Recruiting | 220 | Sep 2026 | Registry ↗ |
| Aug 14, 2026 | Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects NCT04987229 · Bipolar I Disorder, Schizophrenia OLZ/SAM | ALKS Alkermes, Inc. | Phase 3 | Enrolling by invitation | 236 | Sep 2027 | Registry ↗ |
| Aug 4, 2026 | An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipola… NCT07744113 · Bipolar 1 Disorder, Schizophrenia Disorder OLZ/SAM | ALKS Alkermes, Inc. | — | Available | — | — | Registry ↗ |
| Jun 10, 2026 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (A… NCT06358950 · Narcolepsy Type 1 ALKS 2680, Placebo | ALKS Alkermes, Inc. | Phase 2 | Completed | 92 | Jun 19, 2025 | Registry ↗ |
| Feb 27, 2026 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 NCT06555783 · Narcolepsy Type 2 ALKS 2680, Placebo | ALKS Alkermes, Inc. | Phase 2 | Completed | 93 | Nov 11, 2025 | Registry ↗ |
| Sep 26, 2024 | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38… NCT03201757 · Schizophrenia, Schizophreniform Disorder ALKS 3831 | ALKS Alkermes, Inc. | Phase 3 | Completed | 523 | Sep 6, 2023 | Registry ↗ |
| Nov 22, 2023 | Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder NCT04987658 · Bipolar I Disorder OLZ/SAM | ALKS Alkermes, Inc. | Phase 1 | Completed | 7 | Aug 11, 2023 | Registry ↗ |
| Feb 10, 2023 | Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan NCT05547100 · Focus of Study is on Healthy Lactating Women LYBALVI | ALKS Alkermes, Inc. | Phase 1 | Completed | 12 | Nov 19, 2022 | Registry ↗ |
| Feb 2, 2023 | Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS) NCT03919994 · Schizophrenia | ALKS Alkermes, Inc. | — | Completed | 338 | Jan 4, 2023 | Registry ↗ |
| Jan 19, 2023 | Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently D… NCT03187769 · Schizophrenia, Schizophreniform Disorders ALKS 3831, Olanzapine | ALKS Alkermes, Inc. | Phase 3 | Completed | 426 | Dec 1, 2021 | Registry ↗ |
| Sep 2, 2022 | Phase 1 ALKS 1140 in Healthy Adults NCT05019105 · Central Nervous System Diseases Placebo, ALKS 1140 | ALKS Alkermes, Inc. | Phase 1 | Terminated | 20 | Aug 23, 2022 | Registry ↗ |
| Oct 8, 2021 | A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder NCT02161718 · Schizophrenia, Alcohol Use Disorder Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine | ALKS Alkermes, Inc. | Phase 2 | Completed | 300 | Jan 11, 2017 | Registry ↗ |
| Oct 6, 2021 | A Study of ALKS 3831 in Adults With Schizophrenia NCT01903837 · Schizophrenia Samidorphan (Low Dose), Samidorphan (Medium Dose) | ALKS Alkermes, Inc. | Phase 2 | Completed | 347 | Dec 2014 | Registry ↗ |
| Jul 21, 2021 | A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia NCT02873208 · Schizophrenia ALKS 3831 | ALKS Alkermes, Inc. | Phase 3 | Completed | 266 | Oct 17, 2019 | Registry ↗ |
| Jul 16, 2021 | A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) NCT03610048 · Refractory Major Depressive Disorder ALKS 5461 | ALKS Alkermes, Inc. | Phase 3 | Terminated | 175 | May 1, 2020 | Registry ↗ |
| Apr 8, 2021 | A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) NCT03188185 · Major Depressive Disorder ALKS 5461, ALKS 5461 Placebo | ALKS Alkermes, Inc. | Phase 3 | Completed | 278 | Feb 26, 2020 | Registry ↗ |
| Aug 11, 2020 | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia NCT03345979 · Schizophrenia Aripiprazole Lauroxil, Paliperidone Palmitate | ALKS Alkermes, Inc. | Phase 3 | Completed | 200 | Mar 12, 2019 | Registry ↗ |
| Feb 20, 2020 | A 28 Day Parallel Group Study to Assess the Effects of RDN-929 NCT03963973 · Healthy RDN-929 oral capsule, Placebo oral capsule | ALKS Alkermes, Inc. | Phase 1 | Terminated | 7 | Jan 22, 2020 | Registry ↗ |
| Feb 20, 2020 | Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects NCT03668314 · Healthy RDN-929, Placebo oral capsule | ALKS Alkermes, Inc. | Phase 1 | Completed | 84 | Apr 15, 2019 | Registry ↗ |
| Feb 20, 2020 | A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density NCT03577262 · Healthy, Alzheimer Disease [11C]-UCB-J | ALKS Alkermes, Inc. | Early phase 1 | Completed | 19 | Aug 2, 2019 | Registry ↗ |
| Feb 10, 2020 | A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) NCT02694328 · Schizophrenia ALKS 3831, Olanzapine | ALKS Alkermes, Inc. | Phase 3 | Completed | 561 | Nov 7, 2018 | Registry ↗ |
| Aug 14, 2019 | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study NCT02218008 · Major Depressive Disorder ALKS 5461, Placebo | ALKS Alkermes, Inc. | Phase 3 | Completed | 407 | Sep 2016 | Registry ↗ |
| Aug 14, 2019 | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study NCT02158533 · Major Depressive Disorder High Dose ALKS 5461, Low Dose ALKS 5461 | ALKS Alkermes, Inc. | Phase 3 | Completed | 385 | Dec 2015 | Registry ↗ |
| Aug 14, 2019 | A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD) NCT02085135 · Major Depressive Disorder ALKS 5461 | ALKS Alkermes, Inc. | Phase 3 | Completed | 66 | Sep 2014 | Registry ↗ |
| Jul 26, 2019 | A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia NCT02669758 · Schizophrenia ALKS 3831 | ALKS Alkermes, Inc. | Phase 3 | Completed | 281 | Jun 29, 2018 | Registry ↗ |
| Jun 25, 2019 | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study NCT02158546 · Major Depressive Disorder ALKS 5461, Placebo | ALKS Alkermes, Inc. | Phase 3 | Completed | 447 | Dec 2015 | Registry ↗ |
| May 21, 2019 | A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) NCT01500200 · Major Depressive Disorder ALKS 5461, Placebo | ALKS Alkermes, Inc. | Phase 2 | Completed | 142 | Mar 2013 | Registry ↗ |
| Mar 6, 2019 | Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to Fi… NCT02537574 · Opioid Use Disorder NTX/BUP, NTX/PBO-B | ALKS Alkermes, Inc. | Phase 3 | Completed | 380 | Oct 27, 2016 | Registry ↗ |
| Feb 12, 2019 | Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder… NCT02696434 · Opioid Use Disorder Naltrexone, Placebo | ALKS Alkermes, Inc. | Phase 3 | Completed | 101 | Nov 2017 | Registry ↗ |
| Jan 30, 2019 | A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS… NCT01469039 · Schizophrenia ALKS 9072, Placebo | ALKS Alkermes, Inc. | Phase 3 | Completed | 623 | Jan 2014 | Registry ↗ |
| Dec 14, 2018 | A Long-Term Safety Study of ALKS 5461 NCT02141399 · Major Depressive Disorder ALKS 5461 | ALKS Alkermes, Inc. | Phase 3 | Completed | 1,485 | Nov 20, 2017 | Registry ↗ |
| Dec 11, 2018 | ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professio… NCT00834080 · Opiate Dependence Medisorb naltrexone 380 mg | ALKS Alkermes, Inc. | Phase 3 | Completed | 38 | May 2012 | Registry ↗ |
| Dec 4, 2018 | A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia NCT02634320 · Schizophrenia Aripiprazole Lauroxil | ALKS Alkermes, Inc. | Phase 4 | Completed | 51 | Jul 11, 2017 | Registry ↗ |
| Nov 16, 2018 | ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry NCT01422837 · Opioid Dependence | ALKS Alkermes, Inc. | — | Completed | 403 | Oct 2013 | Registry ↗ |
| Sep 25, 2018 | A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) NCT01626456 · Schizophrenia ALKS 9072, Low, ALKS 9072, High | ALKS Alkermes, Inc. | Phase 3 | Completed | 478 | Apr 2015 | Registry ↗ |
| Aug 29, 2018 | An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia NCT02320032 · Schizophrenia Aripiprazole Lauroxil | ALKS Alkermes, Inc. | Phase 1 | Completed | 140 | Apr 2016 | Registry ↗ |
| Aug 29, 2018 | A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia NCT01493726 · Schizophrenia ALKS 9072, Low dose, ALKS 9072, Med dose | ALKS Alkermes, Inc. | Phase 1 | Completed | 88 | Jun 2013 | Registry ↗ |
| Jun 27, 2018 | A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) NCT02634346 · Schizophrenia ALK3831, Olanzapine | ALKS Alkermes, Inc. | Phase 3 | Completed | 403 | May 25, 2017 | Registry ↗ |
| Aug 25, 2017 | An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) NCT01895452 · Schizophrenia ALKS 9072, Low Dose, ALKS 9072, High Dose | ALKS Alkermes, Inc. | Phase 3 | Completed | 291 | Jun 2016 | Registry ↗ |
| Aug 22, 2017 | An Insulin Sensitivity Study in Healthy Subjects NCT02922426 · Healthy Volunteers ALKS 3831, Olanzapine | ALKS Alkermes, Inc. | Phase 1 | Completed | 60 | Jul 20, 2017 | Registry ↗ |
| Jul 11, 2017 | ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults NCT01218958 · Alcoholism Medisorb naltrexone 190 mg, Medisorb naltrexone 380 mg | ALKS Alkermes, Inc. | Phase 3 | Completed | 624 | Sep 2003 | Registry ↗ |
| Jul 11, 2017 | ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alc… NCT00511836 · Alcohol Dependence VIVITROL 380 mg, Placebo | ALKS Alkermes, Inc. | Phase 4 | Completed | 31 | Jun 2009 | Registry ↗ |
| Jul 11, 2017 | ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults NCT00156923 · Alcoholism Medisorb naltrexone 380 mg, Medisorb naltrexone 190 mg | ALKS Alkermes, Inc. | Phase 3 | Completed | 108 | Jan 2007 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:04 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances